Envudeucitinib for Plaque Psoriasis

Envudeucitinib (“envu”), formerly known as ESK-001, is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor designed to correct immune dysregulation across a range of diseases, including plaque psoriasis. By selectively targeting key proinflammatory mediators—IL-23, IL-17, and type 1 interferon (IFN)—it delivers maximal inhibition while minimizing off-target effects.

How it Works

 

STRIDE: Phase 2 Open-label Extension (OLE)

One-year data highlight envu’s potential as a highly differentiated, best-in-class oral TYK2 inhibitor for moderate to severe plaque psoriasis, delivering biologic-like clinical responses while improving patient outcomes, symptom relief, and quality of life.

ONWARD: A Pivotal Phase 3 Program

Topline data from the completed pivotal Phase 3 ONWARD studies (ONWARD 1 and ONWARD 2) are expected in the first quarter of 2026. 

ONWARD 3, an optional long-term extension trial for patients who have completed Week 24 of either the ONWARD 1 or ONWARD 2 studies, is currently ongoing to assess the durability, maintenance of response, and long-term safety of envu.

Envu is also in development for systemic lupus erythematosus (SLE), with potential future indications in psoriatic arthritis, inflammatory bowel disease, and other chronic inflammatory conditions.